Boc-Ser(Me)(Me)-Ser(Me)(Me)-OH | 935888-10-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-Ser(Me)(Me)-Ser(Me)(Me)-OH
• 英文别名: (2S)-3-methoxy-2-[[(2S)-3-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]propanoic acid
• CAS: 935888-10-1
• 化学式: C₁₃H₂₄N₂O₇
• 分子量: 320.343
• InChiKey: MWJGNLLZRTVELR-IUCAKERBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  22
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  123
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Boc-Ser(Me)(Me)-Ser(Me)(Me)-OH 、 (S)-2-amino-1-((R)-2-methyloxiran-2-yl)-3-phenylpropan-1-one trifluoroacetate 在 (S)-2-amino-1-((R)-2-methyloxiran-2-yl)-3-phenylpropan-1-one trifluoroacetate 作用下， 生成 tert-butyl N-[(1S)-2-methoxy-1-{[(1S)-2-methoxy-1-{[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]carbamoyl}ethyl]carbamoyl}ethyl]carbamate
  参考文献：
  名称：

  Crystalline tripeptide epoxy ketone protease inhibitors

  摘要：

  本发明涉及晶体三肽酮环氧化合物、其制备方法及相关药物组合物。

  公开号：

  US09403868B2
• 作为产物：
  描述：

  benzyl (2S)-2-[(2S)-2-{[tert-butoxycarbonyl]amino}-3-methoxypropanamido]-3-methoxypropanoate 生成 Boc-Ser(Me)(Me)-Ser(Me)(Me)-OH
  参考文献：
  名称：

  Crystalline tripeptide epoxy ketone protease inhibitors

  摘要：

  本发明涉及晶体三肽酮环氧化合物、其制备方法及相关药物组合物。

  公开号：

  US09403868B2

文献信息

• Compounds for enzyme inhibition
  申请人：Zhou Han-Jie

  公开号：US20070105786A1

  公开（公告）日：2007-05-10

  Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles

  基于肽的化合物，包括含杂原子的三元环，能够高效且选择性地抑制与蛋白酶体相关的N-末端亲核（Ntn）水解酶的特定活性。这些基于肽的化合物包括环氧化物或氮杂环丙烷，并在N-末端进行官能化。除了其他治疗用途外，预计这些基于肽的化合物将显示抗炎性能和抑制细胞增殖。由于它们的生物利用度特性，这些基于肽的蛋白酶体抑制剂可以通过口服给药进行。
• Crystalline tripeptide epoxy ketone protease inhibitors
  申请人：Onyx Therapeutics, Inc.

  公开号：US09403868B2

  公开（公告）日：2016-08-02

  The invention relates to crystalline tripeptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions.

  本发明涉及晶体三肽酮环氧化合物、其制备方法及相关药物组合物。
• J. Med. Chem. 2009, 52, 3028-3038
  作者：

  DOI：——

  日期：——
• Compounds for Enzyme Inhibition
  申请人：Zhou Han-Jie

  公开号：US20090203698A1

  公开（公告）日：2009-08-13

  Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.
• COMPOUNDS FOR ENZYME INHIBITION
  申请人：Onyx Therapeutics

  公开号：US20130130968A1

  公开（公告）日：2013-05-23

  Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.